In addition to questions about the generalizability of the SOD1G93A model to ALS pathophysiology that is not driven by SOD1 mutations, the aggressive nature of this model presents challenges for preclinical therapeutic experiments. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.